Diaceutics PLC (DXRX) - Total Liabilities
Based on the latest financial reports, Diaceutics PLC (DXRX) has total liabilities worth GBX9.53 Million GBX (≈ $1.16K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore DXRX strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Diaceutics PLC - Total Liabilities Trend (2015–2025)
This chart illustrates how Diaceutics PLC's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Diaceutics PLC asset portfolio.
Diaceutics PLC Competitors by Total Liabilities
The table below lists competitors of Diaceutics PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Smtrack Bhd
KLSE:0169
|
Malaysia | RM23.76 Million |
|
Current Water Technologies Inc
V:WATR
|
Canada | CA$1.66 Million |
|
Capella Minerals Ltd
V:CMIL
|
Canada | CA$1.84 Million |
|
FAT Brands Inc
NASDAQ:FATBB
|
USA | $1.80 Billion |
|
Jaguar Animal Health Inc
NASDAQ:JAGX
|
USA | $29.27 Million |
|
Fsport AB
ST:FSPORT
|
Sweden | Skr1.12 Million |
|
Apogee Minerals Ltd
V:APMI
|
Canada | CA$156.54K |
|
NEVADA SUNRISE METALS
F:K4L
|
Germany | €152.64K |
Liability Composition Analysis (2015–2025)
This chart breaks down Diaceutics PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See DXRX net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Diaceutics PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Diaceutics PLC (2015–2025)
The table below shows the annual total liabilities of Diaceutics PLC from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | GBX9.53 Million ≈ $1.16K |
+8.73% |
| 2024-12-31 | GBX8.76 Million ≈ $1.07K |
+57.66% |
| 2023-12-31 | GBX5.56 Million ≈ $676.25 |
-3.20% |
| 2022-12-31 | GBX5.74 Million ≈ $698.64 |
+31.58% |
| 2021-12-31 | GBX4.36 Million ≈ $530.97 |
+33.01% |
| 2020-12-31 | GBX3.28 Million ≈ $399.20 |
+46.54% |
| 2019-12-31 | GBX2.24 Million ≈ $272.42 |
-56.78% |
| 2018-12-31 | GBX5.18 Million ≈ $630.37 |
+43.37% |
| 2017-12-31 | GBX3.61 Million ≈ $439.69 |
+48.82% |
| 2016-12-31 | GBX2.43 Million ≈ $295.45 |
+106.72% |
| 2015-12-31 | GBX1.17 Million ≈ $142.92 |
-- |
About Diaceutics PLC
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, that en… Read more